World Pharma News Digest - 10.04.2012

1 view
Skip to first unread message

Ruslan David

unread,
Apr 10, 2012, 5:51:12 AM4/10/12
to worldph...@googlegroups.com
Want to place your News, Brand, Service, Product or Event in front of World Pharma News?
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
Read more...
http://www.worldpharmanews.com/contact-us
 
Report says new evidence could tip the balance in aspirin cancer prevention care
‎A new report by American Cancer Society scientists says new data showing aspirin's potential role in reducing the risk of cancer death bring us considerably closer to the time when cancer prevention can be included in clinical guidelines for the use of aspirin in preventative care.
Read more...
http://www.worldpharmanews.com/research/2035-report-says-new-evidence-could-tip-the-balance-in-aspirin-cancer-prevention-care
 
First targeted nanomedicine to enter human clinical studies
‎A team of scientists, engineers and physicians from Brigham and Women's Hospital (BWH), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Massachusetts Institute of Technology (MIT), BIND Biosciences, Translational Genomics Research Institute (TGen), Wayne State University Karmanos Cancer Institute, and Weill Cornell Medical College have found promising effects of a first-in-class targeted cancer drug called BIND-014 in treating solid tumors.
Read more...
http://www.worldpharmanews.com/research/2034-first-targeted-nanomedicine-to-enter-human-clinical-studies
 
Open-source drug research consortium draws a major new champion
‎Takeda Pharmaceutical Company Limited (Takeda) has joined the Structural Genomics Consortium (SGC) to fund collective drug research aimed at bringing new, more effective medicines to market faster. The SGC is based at the Universities of Toronto, Canada, and Oxford, England.
Read more...
http://www.worldpharmanews.com/takeda/2033-open-source-drug-research-consortium-draws-a-major-new-champion
 
Roche sends second letter to Illumina shareholders
‎Roche (SIX: RO, ROG; OTCQX: RHHBY) today sent a second letter to shareholders of Illumina, Inc. (NASDAQ: ILMN) urging them to tender their shares into Roche's increased offer and vote for Roche's independent director nominees and other proposals at the 2012 Illumina annual meeting to be held on 18 April 2012.
Read more...
http://www.worldpharmanews.com/roche/2032-roche-sends-second-letter-to-illumina-shareholders
 
Got a great idea? Submit yours to Grand Challenges Explorations
‎The Bill & Melinda Gates Foundation is accepting applications for Round 9 of its Grand Challenges Explorations initiative, a USD$100 million grant initiative encouraging innovation in global health and development research. Anyone - students, scientists, entrepreneurs - with a transformative idea is invited to submit an easy, online, two-page application.
Read more...
http://www.worldpharmanews.com/development/2031-got-a-great-idea-submit-yours-to-grand-challenges-explorations
 
Roche disappointed by Illumina, Inc.'s Board of Directors' rejection
‎Roche (SIX: RO, ROG; OTCQX: RHHBY) released the following statement in response to the announcement by Illumina, Inc. (NASDAQ: ILMN) that its Board of Directors has recommended that shareholders not tender their shares to Roche's increased offer.
Read more...
http://www.worldpharmanews.com/roche/2030-roche-disappointed-by-illumina-incs-board-of-directors-rejection
 
Neupro® approved by U.S. FDA for Parkinson's disease and Restless Legs Syndrome
‎UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro® (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).
Read more...
http://www.worldpharmanews.com/ucb/2029-neupror-approved-by-us-fda-for-parkinsons-disease-and-restless-legs-syndrome
 
Amgen and AstraZeneca announce collaboration to jointly develop and commercialize clinical-stage inflammation portfolio
‎Amgen (NASDAQ:AMGN) and AstraZeneca Plc, announced an agreement to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).
Read more...
http://www.worldpharmanews.com/amgen/2028-amgen-and-astrazeneca-announce-collaboration-to-jointly-develop-and-commercialize-clinical-stage-inflammation-portfolio
 
Cancer stem cell vaccine in development shows antitumor effect
‎Scientists may have discovered a new paradigm for immunotherapy against cancer by priming antibodies and T cells with cancer stem cells, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.
Read more...
http://www.worldpharmanews.com/research/2027-cancer-stem-cell-vaccine-in-development-shows-antitumor-effect
 
PharmaNews.eu / Latest News
 
 
 
 
 
 
 
European medicines regulators agree a common, Europe-wide approach for the identification of commercially confidential information and personal data
http://www.pharmanews.eu/ema/1027-european-medicines-regulators-agree-a-common-europe-wide-approach-for-the-identification-of-commercially-confidential-information-and-personal-data
 
With best regards,
Ruslan David
Administrator/Editor
 
 
PS: Download World Pharma News' Media Pack (.pdf, 214 KB) http://www.worldpharmanews.com/images/media_pack.pdf
Reply all
Reply to author
Forward
0 new messages